Andrew Rymer is a Partner in Centerview’s healthcare investment banking team. He brings 25 years of experience, advising companies on a variety of strategic matters. Mr. Rymer has established himself as one of the leading healthcare M&A advisors, having worked on some of the industry’s largest and most important transactions, including: Large Pharma - Advised Pfizer in multiple transactions including its $68bn acquisition of Wyeth; its $14bn acquisition of Medivation; its $5bn acquisition of Anacor; and its $18bn OTC JV with Glaxo; Merck in its $3bn acquisition of Antelliq; its spinoff of its Organon division; and its worldwide strategic collaboration with Eisai regarding Lenvima; J&J in its $21bn acquisition of Synthes Biotech – Advised Intra-Cellular Therapies in its $14.6bn sale to J&J; Iveric in its $5.9bn sale to Astellas; Cymabay in its $4.3bn sale to Gilead; Endocyte in its $2.1bn sale to Novartis; Ambrx in its $2bn sale to J&J; CTI Biopharma in its $1.7bn sale to Sobi; Gyroscope Therapeutics in it’s up to $1.5bn sale to Novartis; Micromet in its $1.2 billion sale to Amgen; NeuroDerm in its $1.1bn sale to Mitsubishi Tanabe; Intercept Pharmaceuticals in its $1bn sale to Alfasigma; Nightstar Therapeutics’ in its $877mm sale to Biogen; Curon Biopharmaceutical in its $700mm sale to Merck; G1 Therapeutics in its $405 sale to Pharmacosmos Group; LogicBio in its sale to Alexion (largest biotech premium of all time) Additionally, Mr. Rymer is one the leading advisors in the Pharma Services / CDMO space and has also executed some of the largest LBO transactions, including Medline and athenahealth. Prior to joining Centerview, Mr. Rymer spent 10 years at Goldman Sachs. Mr. Rymer began his career at Donaldson, Lufkin & Jenrette. Mr. Rymer graduated from Dartmouth College and lives in New York City with his wife and three children.